X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14) 14
index medicus (12) 12
melanoma (9) 9
oncology (9) 9
female (8) 8
hematology, oncology and palliative medicine (8) 8
male (8) 8
middle aged (8) 8
disease-free survival (7) 7
metastasis (7) 7
mutation (7) 7
aged (6) 6
cancer (6) 6
melanoma - drug therapy (6) 6
skin cancer (6) 6
adult (5) 5
care and treatment (5) 5
chemotherapy (5) 5
clinical trials (5) 5
medical colleges (5) 5
neoplasm staging (5) 5
abridged index medicus (4) 4
aged, 80 and over (4) 4
analysis (4) 4
authors, german (4) 4
drug therapy (4) 4
germany (4) 4
medicine, general & internal (4) 4
proto-oncogene proteins b-raf - genetics (4) 4
signal transduction (4) 4
skin (4) 4
skin neoplasms - pathology (4) 4
survival (4) 4
treatment outcome (4) 4
biography (3) 3
cutaneous melanoma (3) 3
dermatology (3) 3
drug administration schedule (3) 3
further section (3) 3
imidazoles - administration & dosage (3) 3
internal medicine (3) 3
medical research (3) 3
melanoma - genetics (3) 3
melanoma - mortality (3) 3
melanoma - pathology (3) 3
metastatic melanoma (3) 3
open-label (3) 3
oximes - administration & dosage (3) 3
patient outcomes (3) 3
proto-oncogene proteins b-raf - antagonists & inhibitors (3) 3
risk factors (3) 3
skin neoplasms - diagnosis (3) 3
skin neoplasms - drug therapy (3) 3
skin neoplasms - therapy (3) 3
special section (3) 3
studies (3) 3
tumors (3) 3
vemurafenib (3) 3
1875-1926 (2) 2
adolescent (2) 2
american joint committee (2) 2
aminolevulinate photodynamic therapy (2) 2
anilides - therapeutic use (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic agents, alkylating - therapeutic use (2) 2
article (2) 2
basal cell carcinoma (2) 2
büchner, georg (2) 2
büchner, georg, 1813-1837 (2) 2
cancer therapies (2) 2
carcinoma, basal cell - drug therapy (2) 2
carcinoma, basal cell - pathology (2) 2
dabrafenib plus trametinib (2) 2
dacarbazine (2) 2
dacarbazine - therapeutic use (2) 2
double-blind (2) 2
double-blind method (2) 2
drug dosages (2) 2
epidemiology (2) 2
family medical history (2) 2
follow-up (2) 2
further section · weitere sektionen (2) 2
gene mutations (2) 2
health risk assessment (2) 2
hedgehog pathway (2) 2
imidazoles - adverse effects (2) 2
imidazoles - therapeutic use (2) 2
inhibition (2) 2
life sciences (2) 2
litteraturhistoria: tyska: särskilda författare (2) 2
melanoma - diagnosis (2) 2
melanoma - epidemiology (2) 2
melanoma - secondary (2) 2
melanoma - therapy (2) 2
mohs micrographic surgery (2) 2
oximes - adverse effects (2) 2
oximes - therapeutic use (2) 2
patient safety (2) 2
patients (2) 2
population (2) 2
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Best Practice Onkologie, ISSN 0946-4565, 06/2017, Volume 12, Issue 3-4, pp. 164 - 167
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 386, Issue 9992, pp. 444 - 451
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9839, pp. 358 - 365
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 4, pp. 436 - 444
Summary Background The orally available BRAF kinase inhibitor vemurafenib, compared with dacarbazine, shows improved response rates, progression-free survival... 
Hematology, Oncology and Palliative Medicine
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 08/2015, Volume 13, Issue 8, p. 851
Journal Article
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 08/2015, Volume 13, Issue 8, pp. 851 - 852
Journal Article
The Lancet, ISSN 0140-6736, 09/2018, Volume 392, Issue 10151, pp. 971 - 984
Cutaneous melanoma causes 55 500 deaths annually. The incidence and mortality rates of the disease differ widely across the globe depending on access to early... 
LYMPH-NODE DISSECTION | HIGH-RISK MELANOMA | MEDICINE, GENERAL & INTERNAL | TERT PROMOTER MUTATIONS | DABRAFENIB PLUS TRAMETINIB | STAGE-III MELANOMA | PRIMARY CUTANEOUS MELANOMA | OPEN-LABEL | INVESTIGATOR-CHOICE CHEMOTHERAPY | INDIVIDUAL PATIENT DATA | AMERICAN JOINT COMMITTEE | Melanoma - epidemiology | Melanoma - etiology | Age Distribution | Neoplasm Metastasis - therapy | Skin Neoplasms - therapy | Humans | Risk Factors | Antineoplastic Agents - therapeutic use | Skin Neoplasms - epidemiology | Ultraviolet Rays - adverse effects | Incidence | Randomized Controlled Trials as Topic | Sunlight - adverse effects | Mass Screening | Protein Kinase Inhibitors - therapeutic use | Skin Neoplasms - mortality | Skin Neoplasms - etiology | Melanoma - therapy | Neoplasm Staging | Melanoma - mortality | Medical colleges | Mortality | Melanoma | Antibodies | Metastasis | Epidemiology | Viral antibodies | Analysis | Skin | Mitogens | Protein kinases | Germany | Medical informatics | Medical innovations | Clinical trials | Raf protein | Family medical history | Kinases | Cancer therapies | Metastases | Skin cancer | Proteins | Signal transduction | Age | Containment | Medical research | Threonine | MAP kinase | Protein kinase inhibitors | Survival | Chemotherapy | Sunburn & sun tanning | Inhibitors | Cell death | Mutation | Health risk assessment | Prolongation | Cancer | Tumors
Journal Article